Full Name: Dr. ALI HAIDER ALHAMMER Gender: Male Birthdate: 1984 Nationality: Iraq Degree: PhD Academic Title: Lecturer College\Center: Biotechnology Research Center
Departement: - Major: Biotechnology Specialty: Cancer and Stem Cells Biology Mother Language: Arabic Other Languages: English Work email: ali.alhammer@nahrainuniv.edu.iq Personal email: alialhammer@gmail.com
EDUCATION
PhD in Cancer and Stem cells (targeted therapies for Acute Lymphoblastic Leukemia stem cells) Apr 2014 — Mar 2018
Northern Institute for Cancer Research, Newcastle University, UK (Link: https://www.ncl.ac.uk/cancer/)
PhD Thesis: Exploring the Pre-B cell receptor checkpoint as a therapeutic target in acute lymphoblastic leukaemia
SKILLS AND QUALIFICATIONS
Research experience:
1. Formation and analysis of xenografts from primary derived material – monitoring of mice and subsequent dissection and procession of spleen cells for downstream analyses
2. Mouse tail vein bleeds – tracking peripheral blood engraftment of leukaemia in mice by Flowcytometry (MRD analysis)
3. Assessment of drug sensitivity of single and combinations in vitro and ex vivo –resazurin assay to assess the drug sensitivity of cell lines and xenograft cells
4. Culture of leukaemia and lymphoma suspension cells in addition to adherent cells of breast, pancreatic tumor cells
5. Western blotting
6. Flowcytometry to assess-Intracellular phospho-profiling, Ca mobilisation, cell surface markers, Immunophenotyping, cell cycle profile and apoptosis.
9. Software application to calculate combination indecies (CalcuSyn).
10. Supervising undergraduate last year project for a student at the Northern Institute of Cancer Research, Newcastle University.
Research Interest
I am an academic researcher specializing in cancer and stem cell research. I did my PhD studies at the Northern Institute for Cancer Research at Newcastle University in the United Kingdom.
My current research focuses on:
Defining Novel Therapeutic Targets: I systematically investigate abnormal cellular pathways in cancer cells to identify actionable protein candidates that can eradicate or inhibit the growth of cancer cells.
Combination Therapy Optimization: I evaluate the synergistic effects of these novel targets with established chemotherapeutic agents, aiming to enhance efficacy and overcome treatment resistance. This includes testing targeted and newly developed therapies worldwide in combination with classical chemotherapies against breast, prostate and pancreatic cancer cells in vitro.
In Vivo Model Development: I am actively working on establishing an immunocompromised mouse model for the transplantation of cancer and stem cells, bridging the gap between in vitro findings and preclinical validation, and paving the way for advanced in vivo studies.
RESEARCH EXPERIENCE
SUPERVISOR THESIS
Isolation of mesenchymal stem cells, Suspension cell culture, PCR, RT-qPCR, Tissue Culture, Western Blot, Analysis Gel Electrophoresis, Flow Cytometry, Immunophenotyping, Ca mobilization assay, Intracellular phosphoprofiling assay, Electrophoresis, ELISA assay, Cancer Biology, SDS-PAGE, Adherent cell Culture, RNA Isolation, Cell Signaling, DNA Extraction, Cellular Biology, GraphPad Prism, Small Animal Handling, Cell Viability, Immunocompromised mice Handling, Blood Collection, In Vivo Study.
Others
Other skills:
Clonogenic Assay, Fluorescence microscopy, Amplification of human cancer cells in Xenograft mouse Model, Establishment of human tumors in immuno-sppressed mice, Annexin V Apoptosis Assays, Acridine orange-Ethidium bromide Apoptosis Assays, Wound healing (scratch assay).